Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. NC4007636

AURORA BIOLABS LLC TR-FRET Cereblon-4C Binding Assay Kit,384 rxn

Catalog No. NC4007636
Encompass_Preferred

E3 ubiquitin ligases are enzymes that catalyze the final step of the ubiquitination process and play essential roles in targeted protein degradation. Cereblon (CRBN) is the substrate-recognition component of the CRBN/DDB1/CUL4A/RBX1 E3 ubiquitin ligase complex and is widely used in PROTAC (Proteolysis-Targeting Chimera) drug discovery for targeted protein degradation applications. The TR-FRET Cereblon-4C Binding Assay Kit is designed to quantitatively measure the binding interaction between CRBN and its ligands. The assay includes Tag1-CRBN-4C complex, terbium-labeled anti-Tag1 antibody, and fluorescently labeled thalidomide ligand. Binding of CRBN to thalidomide generates a fluorescence resonance energy transfer (FRET) signal detected by measuring fluorescence emission at 665 nm and 620 nm. Compounds that compete with thalidomide for CRBN binding reduce the HTRF signal, enabling evaluation of CRBN-targeting molecules for drug discovery and PROTAC research applications.

Catalog No. NC4007636 Supplier AURORA BIOLABS LLC Supplier No. 272625384
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

E3 ubiquitin ligases are enzymes that catalyze the final step of the ubiquitination process and play essential roles in targeted protein degradation. Cereblon (CRBN) is the substrate-recognition component of the CRBN/DDB1/CUL4A/RBX1 E3 ubiquitin ligase complex and is widely used in PROTAC (Proteolysis-Targeting Chimera) drug discovery for targeted protein degradation applications. The TR-FRET Cereblon-4C Binding Assay Kit is designed to quantitatively measure the binding interaction between CRBN and its ligands. The assay includes Tag1-CRBN-4C complex, terbium-labeled anti-Tag1 antibody, and fluorescently labeled thalidomide ligand. Binding of CRBN to thalidomide generates a fluorescence resonance energy transfer (FRET) signal detected by measuring fluorescence emission at 665 nm and 620 nm. Compounds that compete with thalidomide for CRBN binding reduce the HTRF signal, enabling evaluation of CRBN-targeting molecules for drug discovery and PROTAC research applications.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.